InsiderSignal.AI

InsiderSignal.ai

LQDA - Liquidia Corp

Insider Sale by Adair Jason (Chief Business Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Adair Jason, serving as Chief Business Officer at Liquidia Corp (LQDA), sold 688 shares at $41.65 per share, for a total transaction value of $28,655.00. Following this transaction, Adair Jason now holds 214,738 shares of LQDA.

The trade was executed on Monday, April 27, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 29, 2026, 2 days after the trade was made.

Liquidia Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Adair Jason

Adair Jason

Chief Business Officer

Jason Adair is an experienced biotechnology executive serving as Chief Business Officer at Liquidia Corp (LQDA), where he owns approximately 212,479 shares worth over $8 million[[2]](https://www.gurufocus.com/insider/126616/jason-adair). He joined Liquidia Technologies in January 2016 as Vice President of Corporate Development & Strategy, leading the company's business development activities, including partnering and licensing initiatives, while playing a key role in executing long-term commercial strategy[[3]](https://www.fiercebiotech.com/biotech/liquidia-technologies-inc-names-jason-adair-vice-president-business-development-strategy). Adair brings extensive experience across the biotechnology sector. Previously, he led business development efforts at BioCryst Pharmaceuticals, where he oversaw the commercial launch and partnering of the company's first FDA-approved influenza drug and managed international alliances in Japan, Korea, Israel, and the United Kingdom[[3]](https://www.fiercebiotech.com/biotech/liquidia-technologies-inc-names-jason-adair-vice-president-business-development-strategy). Before BioCryst, he held positions of increasing responsibility in business development, marketing, and operations at MedImmune/AstraZeneca in the biologics field[[3]](https://www.fiercebiotech.com/biotech/liquidia-technologies-inc-names-jason-adair-vice-president-business-development-strategy). He began his career as an analytical chemist at Syngenta and served as an officer in the United States Army[[3]](https://www.fiercebiotech.com/biotech/liquidia-technologies-inc-names-jason-adair-vice-president-business-development-strategy). Adair holds a Bachelor of Science from Wake Forest University and an MBA from the Tuck School of Business at Dartmouth College[[3]](https://www.fiercebiotech.com/biotech/liquidia-technologies-inc-names-jason-adair-vice-president-business-development-strategy).

View full insider profile →

Trade Price

$41.65

Quantity

688

Total Value

$28,655.00

Shares Owned

214,738

Trade Date

Monday, April 27, 2026

4 days ago

SEC Filing Date

Wednesday, April 29, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning LQDA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6051564

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime